Cardiovascular disease (CVD) diagnosis and treatment are challenging since
symptoms appear late in the disease’s progression. Despite clinical risk scores,
cardiac event prediction is inadequate, and many at-risk patients are not
adequately categorised by conventional risk factors alone. Integrating
genomic-based biomarkers (GBBM), specifically those found in plasma and/or serum
samples, along with novel non-invasive radiomic-based biomarkers (RBBM) such as
plaque area and plaque burden can improve the overall specificity of CVD risk.
This review proposes two hypotheses: (i) RBBM and GBBM biomarkers have a strong
correlation and can be used to detect the severity of CVD and stroke precisely,
and (ii) introduces a proposed artificial intelligence (AI)—based preventive,
precision, and personalized (
) CVD/Stroke risk model. The PRISMA search
selected 246 studies for the CVD/Stroke risk. It showed that using the RBBM and
GBBM biomarkers, deep learning (DL) modelscould be used for CVD/Stroke risk
stratification in the
framework. Furthermore, we present a concise
overview of platelet function, complete blood count (CBC), and diagnostic
methods. As part of the AI paradigm, we discuss explainability, pruning, bias,
and benchmarking against previous studies and their potential impacts. The review
proposes the integration of RBBM and GBBM, an innovative solution streamlined in
the DL paradigm for predicting CVD/Stroke risk in the
framework. The
combination of RBBM and GBBM introduces a powerful CVD/Stroke risk assessment
paradigm.
model signifies a promising advancement in CVD/Stroke risk
assessment.